Budesonide + formoterol

**Indication**: Asthma  
**ICD11 code**: CA23

**INN**: Budesonide + formoterol

**Medicine type**: Chemical agent

**List type**: Core

**Formulations**: Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose

**EML status history**:  
First added in 2017 (TRS 1006)  
Changed in 2021 (TRS 1035)

**Sex**: All

**Age**: Adolescents and adults

**Therapeutic alternatives**:  
- budesonide + salmeterol (ATC codes: R03AK12)  
- beclometasone + formoterol (ATC codes: R03AK08)  
- mometasone + formoterol (ATC codes: R03AK09)  
- fluticasone + formoterol (ATC codes: R03AK11)  
- fluticasone furoate + vilanterol (ATC codes: R03AK10)

**Patent information**: Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**: Budesonide + formoterol

**DrugBank**:  
- Budesonide
  - Formoterol

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the following be specified as therapeutic alternatives under the square box listing for budesonide + formoterol for treatment of asthma on the EML:  
beclometasone + formoterol, budesonide + salmeterol, fluticasone + formoterol, fluticasone furoate + vilanterol, and mometasone + formoterol.